The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during 2024--2032. Growth is underpinned by ...
Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...
Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...
MedPage Today on MSN
Cancer Drug Pulled From Market Over Safety Concerns
Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...
Skysona will now only be indicated for patients without an available HLA-matched allogeneic hematopoietic stem cell donor. The Food and Drug Administration (FDA) has approved new safety labeling ...
Integrating Palliative Care and Hematologic Malignancies: Bridging the Gaps for Our Patients and Their Caregivers. If you have the appropriate software installed, you can download article citation ...
Women diagnosed with hematological malignancies during pregnancy face higher severe maternal morbidity and obstetric complications compared to post-pregnancy diagnoses. The study analyzed data from ...
Please provide your email address to receive an email when new articles are posted on . GLP-1 use appeared associated with reduced risk for various blood cancers in patients with type 2 diabetes. The ...
One in 10 childhood blood cancers may result from medical imaging-associated radiation exposure. Cancer risk increased with cumulative radiation dose, ranging from 1.41 times higher to 3.59 times ...
AMH versus AFC in women with cancer: an abstract from the 2026 Annual Congress of the International Society of Gynecological Endocrinology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results